ConductScience.org, home

Paper36934740

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.

Loomba R and 11 others. Lancet Gastroenterol Hepatol, 2023. Cited by 468 papers, by iCite.

Cite this record

ConductScience Library. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Papers, record 36934740. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36934740

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
PubMed
Journal
Lancet Gastroenterol Hepatol
PubMed
Year
2023
PubMed
Publication types
Randomized Controlled Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
468
iCite
Relative citation ratio, by iCite
51
iCite
Revised in PubMed
2026-01-27
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Loomba RRohit
2Abdelmalek MFManal F
3Armstrong MJMatthew J
4Jara MMaximilian
5Kjær MSMette Skalshøi
6Krarup NNiels
7Lawitz EEric
8Ratziu VVlad
9Sanyal AJArun J
10Schattenberg JMJörn M
11Newsome PNPhilip N
12NN9931-4492 investigatorsGroup

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Diabetes Mellitus, Type 2Major topic
Non-alcoholic Fatty Liver DiseaseMajor topic
Adult
Humans
Male
Female
Middle Aged
Glucagon-Like Peptide 1
Liver Cirrhosis
Semaglutide

Source PubMed

Download CSV of topics

Grants10

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
U01 DK130190NIDDK NIH HHSUnited StatesU01DK130190PubMed and NIHNIH RePORTER
UL1 TR001442NCATS NIH HHSUnited StatesUL1TR001442PubMed and NIHNIH RePORTER
Department of HealthUnited KingdomPubMedPubMed
P30 DK120515NIDDK NIH HHSUnited StatesP30DK120515PubMed and NIHNIH RePORTER
U01 AA029019NIAAA NIH HHSUnited StatesU01AA029019PubMed and NIHNIH RePORTER
R01 DK124318NIDDK NIH HHSUnited StatesR01DK124318PubMed and NIHNIH RePORTER
U01 DK061734NIDDK NIH HHSUnited StatesU01DK061734PubMed and NIHNIH RePORTER
P01 HL147835NHLBI NIH HHSUnited StatesP01HL147835PubMed and NIHNIH RePORTER
R01 DK121378NIDDK NIH HHSUnited StatesR01DK121378PubMed and NIHNIH RePORTER
R01 DK106419NIDDK NIH HHSUnited StatesR01DK106419PubMed and NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03987451A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver DamageBackgroundYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in36934739Semaglutide in NASH-related cirrhosis: too late to the party?https://conductscience.org/library/papers/36934739PubMed
Comment in37453428Semaglutide in NASH-related cirrhosis: still a long way to go?https://conductscience.org/library/papers/37453428PubMed

Download CSV of comments and corrections

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133570776A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.Hepatology2021https://conductscience.org/library/papers/33570776PubMed
230144956EASL Clinical Practice Guidelines on nutrition in chronic liver disease.J Hepatol2019https://conductscience.org/library/papers/30144956PubMed
331309602Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease.Hepatology2020https://conductscience.org/library/papers/31309602PubMed
44950264Surgery and portal hypertension.Major Probl Clin Surg1964https://conductscience.org/library/papers/4950264PubMed
532027911Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Gastroenterology2020https://conductscience.org/library/papers/32027911PubMed
634555346Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.Lancet Gastroenterol Hepatol2021https://conductscience.org/library/papers/34555346PubMed
734927277Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality.Aliment Pharmacol Ther2022https://conductscience.org/library/papers/34927277PubMed
830615985Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.Diabetes Metab2019https://conductscience.org/library/papers/30615985PubMed
928802062Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology2018https://conductscience.org/library/papers/28802062PubMed
1026608256Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.Lancet2016https://conductscience.org/library/papers/26608256PubMed
1131537030Peculiarities of Cirrhosis due to Nonalcoholic Steatohepatitis (NASH).Semin Liver Dis2020https://conductscience.org/library/papers/31537030PubMed
1233567185Once-Weekly Semaglutide in Adults with Overweight or Obesity.N Engl J Med2021https://conductscience.org/library/papers/33567185PubMed
1326047908Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.J Hepatol2015https://conductscience.org/library/papers/26047908PubMed
1434822801Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.Gastroenterology2022https://conductscience.org/library/papers/34822801PubMed
1530222962Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.Gastroenterology2019https://conductscience.org/library/papers/30222962PubMed
1633989548Mechanisms and disease consequences of nonalcoholic fatty liver disease.Cell2021https://conductscience.org/library/papers/33989548PubMed
1715915461Design and validation of a histological scoring system for nonalcoholic fatty liver disease.Hepatology2005https://conductscience.org/library/papers/15915461PubMed
1833724511Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.Hepatology2021https://conductscience.org/library/papers/33724511PubMed
1929990488Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.Gastroenterology2018https://conductscience.org/library/papers/29990488PubMed
2027062661EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.J Hepatol2016https://conductscience.org/library/papers/27062661PubMed

See all 32 referencesDownload CSV of references

Cited by292

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 468 citations.

PMIDTitleJournalYearIn PapersSource
42942139Chronic Intermittent Hypoxia and MASLD in Obstructive Sleep Apnea: A Critical Appraisal of Mechanistic and Causal Evidence.Int J Mol Sci2026https://conductscience.org/library/papers/42942139PubMed
42889937Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity.Diabetes Obes Cardiometab CARE2026https://conductscience.org/library/papers/42889937PubMed
42882002MetALD in Clinical Practice: Diagnosis, Non-Invasive Risk Stratification, and Management.J Clin Med2026https://conductscience.org/library/papers/42882002PubMed
42872191Metabolic dysfunction-associated steatotic liver disease assessment and management: Clinical practice guidance from the Canadian Association for the Study of the Liver.Can Liver J2026https://conductscience.org/library/papers/42872191PubMed
42862908Cardiovascular Complications of Chronic Liver Disease.Circulation2026https://conductscience.org/library/papers/42862908PubMed
42851902Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42851902PubMed
42825923Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia2026https://conductscience.org/library/papers/42825923PubMed
42825265Semaglutide for MASH cirrhosis: a new therapeutic frontier or a false dawn?eGastroenterology2026https://conductscience.org/library/papers/42825265PubMed
42792628Pathogenesis-Informed Phenotype-Guided Therapy for MASH: A Three-Axis Translational Framework Within the MASLD Spectrum.Biomedicines2026https://conductscience.org/library/papers/42792628PubMed
42741872Low Steatosis May Signal Failing Reserve in Cirrhosis due to Metabolic Dysfunction-Associated Steatotic Liver Disease.Liver Int2026https://conductscience.org/library/papers/42741872PubMed
42737685The Effect of Prolyl Isomerase Pin1 on the Development of Metabolic Dysfunction-Associated Steatohepatitis and a New Treatment Strategy.Int J Mol Sci2026https://conductscience.org/library/papers/42737685PubMed
42713454Glucagon-Like Peptide-1 Receptor Agonist Use Before and After Liver Transplant.Gastroenterol Hepatol (N Y)2026https://conductscience.org/library/papers/42713454PubMed
42712610Effects and safety of Huatan Qushi Huoxue granules on obesity-associated non-alcoholic fatty liver disease: a multicenter, randomized, double-blind, placebo-controlled trial.Front Pharmacol2026https://conductscience.org/library/papers/42712610PubMed
42697203Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis.Cell Rep Med2026https://conductscience.org/library/papers/42697203PubMed
42690550Emerging Topics In Obesity Treatment in the Setting of Organ Transplantation.Curr Obes Rep2026https://conductscience.org/library/papers/42690550PubMed
42687024Current therapeutic landscape and future treatment perspectives of MASH.Nature2026https://conductscience.org/library/papers/42687024PubMed
42683225Mechanobiological feedback loops and quantitative decision thresholds in organ fibrosis: Translational principles for antifibrotic therapy.J Cell Commun Signal2026https://conductscience.org/library/papers/42683225PubMed
42683000Bile acid-axis dysregulation in MASLD/MASH progression: from metabolic mismatch to inflammatory-fibrotic remodeling.Front Med (Lausanne)2026https://conductscience.org/library/papers/42683000PubMed
42670691Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies.Gut Liver2026https://conductscience.org/library/papers/42670691PubMed
42666665Mapping GLP-1 receptor agonist research across the MASLD-MASH-HCC continuum: a bibliometric and translational analysis.Front Med (Lausanne)2026https://conductscience.org/library/papers/42666665PubMed

See all 292 cited byDownload CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36934740

GET https://conductscience.org/api/papers/v1/36934740/references?page=2